MX2020002571A - Derivados de 1-(4-(isoxazol-5-il)-1h-pirazol-1-il)-2-metilpropan-2 -ol y compuestos relacionados como inhibidores de il-17 e ifn-gamma para tratar enfermedades autoinmunes e inflamacion cronica. - Google Patents
Derivados de 1-(4-(isoxazol-5-il)-1h-pirazol-1-il)-2-metilpropan-2 -ol y compuestos relacionados como inhibidores de il-17 e ifn-gamma para tratar enfermedades autoinmunes e inflamacion cronica.Info
- Publication number
- MX2020002571A MX2020002571A MX2020002571A MX2020002571A MX2020002571A MX 2020002571 A MX2020002571 A MX 2020002571A MX 2020002571 A MX2020002571 A MX 2020002571A MX 2020002571 A MX2020002571 A MX 2020002571A MX 2020002571 A MX2020002571 A MX 2020002571A
- Authority
- MX
- Mexico
- Prior art keywords
- autoimmune diseases
- chronic inflammation
- methylpropan
- isoxazol
- pyrazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula general (I), y las sales y solvatos farmacéuticamente aceptables de los mismos, en los cuales Ar, Z y Y son como se describen en la presente solicitud y R1 es un grupo de la estructura (ver Fórmula) en la cual n es 0 o 1; R2 es H, deuterio o metilo; R3 es metilo, trifluorometilo, etilo, o tomado con R2 juntos forman un grupo ciclopropilo, o R3 forma un puente de metileno al átomo de carbono marcado con *, los cuales son apropiados para el tratamiento de enfermedades autoinmunes e inflamación crónica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17189652 | 2017-09-06 | ||
| PCT/EP2018/073993 WO2019048541A1 (en) | 2017-09-06 | 2018-09-06 | 1- (4- (ISOXAZOL-5-YL) -1H-PYRAZOL-1-YL) -2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF IL-17 AND IFN- GAMMA FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002571A true MX2020002571A (es) | 2020-10-01 |
Family
ID=59799324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002571A MX2020002571A (es) | 2017-09-06 | 2018-09-06 | Derivados de 1-(4-(isoxazol-5-il)-1h-pirazol-1-il)-2-metilpropan-2 -ol y compuestos relacionados como inhibidores de il-17 e ifn-gamma para tratar enfermedades autoinmunes e inflamacion cronica. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11292788B2 (es) |
| EP (2) | EP4074708A1 (es) |
| JP (2) | JP2020532575A (es) |
| KR (1) | KR20200069299A (es) |
| CN (1) | CN111433202A (es) |
| AU (1) | AU2018330633C1 (es) |
| CA (1) | CA3074891A1 (es) |
| CY (1) | CY1125514T1 (es) |
| DK (1) | DK3679034T3 (es) |
| ES (1) | ES2925538T3 (es) |
| HR (1) | HRP20221042T1 (es) |
| HU (1) | HUE059822T2 (es) |
| IL (1) | IL273064B2 (es) |
| LT (1) | LT3679034T (es) |
| MA (1) | MA50069B1 (es) |
| MD (1) | MD3679034T2 (es) |
| MX (1) | MX2020002571A (es) |
| PH (1) | PH12020500461A1 (es) |
| PL (1) | PL3679034T3 (es) |
| PT (1) | PT3679034T (es) |
| RS (1) | RS63532B1 (es) |
| SG (1) | SG11202001409UA (es) |
| SI (1) | SI3679034T1 (es) |
| SM (1) | SMT202200343T1 (es) |
| UA (1) | UA126689C2 (es) |
| WO (1) | WO2019048541A1 (es) |
| ZA (1) | ZA202001179B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020532575A (ja) * | 2017-09-06 | 2020-11-12 | イミュニック アクチェンゲゼルシャフト | 自己免疫疾患及び慢性炎症を治療するためのｉｌ−１７及びｉｆｎ−ガンマの阻害剤としての１−（４−（イソオキサゾール−５−イル）−１ｈ−ピラゾール−１−イル）−２−メチルプロパン−２−オール誘導体及び関連化合物 |
| WO2023281097A1 (en) | 2021-07-09 | 2023-01-12 | Immunic Ag | Methods for treating cancer |
| CN113683505A (zh) * | 2021-09-29 | 2021-11-23 | 厦门大华本安化工安全研究院有限公司 | 一种含氧代环丁基的羧酸酯类化合物的制备方法 |
| US20250243190A1 (en) | 2022-04-14 | 2025-07-31 | Immunic Ag | New deuterated rorgamma/rorgammat inverse agonists |
| WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
| CN119192167B (zh) * | 2024-11-28 | 2025-03-21 | 英矽智能科技(上海)有限公司 | 一类抑制il-17的化合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2664219T3 (es) * | 2011-01-28 | 2018-04-18 | Immunic Ag | Inhibición de IL17 e IFN-gamma para el tratamiento de una inflamación autoinmunitaria |
| JP5969505B2 (ja) | 2011-01-28 | 2016-08-17 | ４エスツェー ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツング | 自己免疫性炎症の治療のためのＩＬ１７及びＩＦＮ−γ阻害 |
| JP2020532575A (ja) * | 2017-09-06 | 2020-11-12 | イミュニック アクチェンゲゼルシャフト | 自己免疫疾患及び慢性炎症を治療するためのｉｌ−１７及びｉｆｎ−ガンマの阻害剤としての１−（４−（イソオキサゾール−５−イル）−１ｈ−ピラゾール−１−イル）−２−メチルプロパン−２−オール誘導体及び関連化合物 |
-
2018
- 2018-09-06 JP JP2020514532A patent/JP2020532575A/ja active Pending
- 2018-09-06 CA CA3074891A patent/CA3074891A1/en active Pending
- 2018-09-06 MA MA50069A patent/MA50069B1/fr unknown
- 2018-09-06 KR KR1020207009871A patent/KR20200069299A/ko not_active Ceased
- 2018-09-06 PL PL18762111.5T patent/PL3679034T3/pl unknown
- 2018-09-06 CN CN201880058056.9A patent/CN111433202A/zh active Pending
- 2018-09-06 SG SG11202001409UA patent/SG11202001409UA/en unknown
- 2018-09-06 LT LTEPPCT/EP2018/073993T patent/LT3679034T/lt unknown
- 2018-09-06 MX MX2020002571A patent/MX2020002571A/es unknown
- 2018-09-06 UA UAA202002206A patent/UA126689C2/uk unknown
- 2018-09-06 SM SM20220343T patent/SMT202200343T1/it unknown
- 2018-09-06 DK DK18762111.5T patent/DK3679034T3/da active
- 2018-09-06 MD MDE20200707T patent/MD3679034T2/ro unknown
- 2018-09-06 HR HRP20221042TT patent/HRP20221042T1/hr unknown
- 2018-09-06 PT PT187621115T patent/PT3679034T/pt unknown
- 2018-09-06 AU AU2018330633A patent/AU2018330633C1/en not_active Ceased
- 2018-09-06 SI SI201830741T patent/SI3679034T1/sl unknown
- 2018-09-06 EP EP22176185.1A patent/EP4074708A1/en not_active Withdrawn
- 2018-09-06 US US16/644,581 patent/US11292788B2/en active Active
- 2018-09-06 WO PCT/EP2018/073993 patent/WO2019048541A1/en not_active Ceased
- 2018-09-06 ES ES18762111T patent/ES2925538T3/es active Active
- 2018-09-06 HU HUE18762111A patent/HUE059822T2/hu unknown
- 2018-09-06 RS RS20220796A patent/RS63532B1/sr unknown
- 2018-09-06 EP EP18762111.5A patent/EP3679034B1/en active Active
-
2020
- 2020-02-25 ZA ZA2020/01179A patent/ZA202001179B/en unknown
- 2020-03-04 IL IL273064A patent/IL273064B2/en unknown
- 2020-03-06 PH PH12020500461A patent/PH12020500461A1/en unknown
-
2022
- 2022-08-25 CY CY20221100574T patent/CY1125514T1/el unknown
- 2022-12-23 JP JP2022206807A patent/JP2023052060A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020002571A (es) | Derivados de 1-(4-(isoxazol-5-il)-1h-pirazol-1-il)-2-metilpropan-2 -ol y compuestos relacionados como inhibidores de il-17 e ifn-gamma para tratar enfermedades autoinmunes e inflamacion cronica. | |
| CL2019003747A1 (es) | Amidas heterocíclicas de 5 miembros y bicíclicas como inhibidores de rock. | |
| CY1125784T1 (el) | Υποκατεστημενες δικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις της prmt5 | |
| EA201691302A1 (ru) | Новые гетероциклические соединения | |
| UY37073A (es) | Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen | |
| CY1122046T1 (el) | Δικυκλικα ετεροκυκλικα παραγωγα ως αναστολεις βρομοτομεων | |
| EA201592199A1 (ru) | Производные бипиразола в качестве ингибиторов jak | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| DOP2015000158A (es) | Inhibidores de prmt5 y sus usos | |
| EA201790202A1 (ru) | Фталазиноны и изохинолиноны в качестве ингибиторов rock | |
| EA201890307A1 (ru) | Индазольные и азаиндазольные соединения как ингибиторы irak-4 | |
| MX2017004906A (es) | Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma. | |
| EA201692418A1 (ru) | Замещенные индазольные соединения в качестве irak4 ингибиторов | |
| EA201491671A1 (ru) | Гетероциклильные соединения | |
| MX390747B (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| AR101210A1 (es) | Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| EA201692268A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| EA201690888A1 (ru) | Новые гетероциклические соединения | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| EA201791289A1 (ru) | Ингибиторы клеточного некроза и связанные с ними способы | |
| UA124939C2 (uk) | СПОСІБ ЗБІЛЬШЕННЯ КОНЦЕНТРАЦІЇ ДЕЗОКСІУРИДИНУ (dUrd) В ПЛАЗМІ У СУБ’ЄКТА-ЛЮДИНИ | |
| JOP20190050A1 (ar) | مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي |